These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 33670655)
1. The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo. Alburquerque-González B; Bernabé-García Á; Bernabé-García M; Ruiz-Sanz J; López-Calderón FF; Gonnelli L; Banci L; Peña-García J; Luque I; Nicolás FJ; Cayuela-Fuentes ML; Luchinat E; Pérez-Sánchez H; Montoro-García S; Conesa-Zamora P Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670655 [TBL] [Abstract][Full Text] [Related]
2. Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells. Montoro-García S; Alburquerque-González B; Bernabé-García Á; Bernabé-García M; Rodrigues PC; den-Haan H; Luque I; Nicolás FJ; Pérez-Sánchez H; Cayuela ML; Salo T; Conesa-Zamora P J Mol Med (Berl); 2020 Mar; 98(3):383-394. PubMed ID: 31996952 [TBL] [Abstract][Full Text] [Related]
3. New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells. Alburquerque-González B; Bernabé-García M; Montoro-García S; Bernabé-García Á; Rodrigues PC; Ruiz Sanz J; López-Calderón FF; Luque I; Nicolas FJ; Cayuela ML; Salo T; Pérez-Sánchez H; Conesa-Zamora P Exp Mol Med; 2020 Feb; 52(2):281-292. PubMed ID: 32080340 [TBL] [Abstract][Full Text] [Related]
4. Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial. Asensi-Cantó A; Rodríguez-Braun E; Beltrán-Videla A; Hurtado AM; Conesa-Zamora P Front Oncol; 2023; 13():1238464. PubMed ID: 37841433 [TBL] [Abstract][Full Text] [Related]
5. Fascin1 suppresses RIG-I-like receptor signaling and interferon-β production by associating with IκB kinase ϵ (IKKϵ) in colon cancer. Matsumura T; Hida S; Kitazawa M; Fujii C; Kobayashi A; Takeoka M; Taniguchi SI; Miyagawa SI J Biol Chem; 2018 Apr; 293(17):6326-6336. PubMed ID: 29496994 [TBL] [Abstract][Full Text] [Related]
6. Migrastatin analogues inhibit canine mammary cancer cell migration and invasion. Majchrzak K; Lo Re D; Gajewska M; Bulkowska M; Homa A; Pawłowski K; Motyl T; Murphy PV; Król M PLoS One; 2013; 8(10):e76789. PubMed ID: 24116159 [TBL] [Abstract][Full Text] [Related]
7. Upregulation of fascin-1 is involved in HIF-1α-dependent invasion and migration of hypopharyngeal squamous cell carcinoma. Bu M; Liu X; Liu X; Xu W Int J Oncol; 2019 Aug; 55(2):488-498. PubMed ID: 31268159 [TBL] [Abstract][Full Text] [Related]
8. TGF-β1 promotes the migration and invasion of bladder carcinoma cells by increasing fascin1 expression. Zhang N; Bi X; Zeng Y; Zhu Y; Zhang Z; Liu Y; Wang J; Li X; Bi J; Kong C Oncol Rep; 2016 Aug; 36(2):977-83. PubMed ID: 27350089 [TBL] [Abstract][Full Text] [Related]
9. Fascin1 in carcinomas: Its regulation and prognostic value. Ma Y; Machesky LM Int J Cancer; 2015 Dec; 137(11):2534-44. PubMed ID: 25302416 [TBL] [Abstract][Full Text] [Related]
10. Knockdown of fascin1 expression suppresses the proliferation and metastasis of gastric cancer cells. Fu H; Wen JF; Hu ZL; Luo GQ; Ren HZ Pathology; 2009; 41(7):655-60. PubMed ID: 20001345 [TBL] [Abstract][Full Text] [Related]
11. TGF-β1 induced fascin1 expression facilitates the migration and invasion of kidney carcinoma cells through ERK and JNK signaling pathways. Yang J; Zhang N; Gao R; Zhu Y; Zhang Z; Xu X; Wang J; Li Z; Liu X; Li Z; Li J; Bi J; Kong C Biochem Biophys Res Commun; 2018 Jul; 501(4):913-919. PubMed ID: 29772238 [TBL] [Abstract][Full Text] [Related]
12. Fascin1 promotes gastric cancer progression by facilitatingcell migrationand epithelial-mesenchymal transition. Wang G; Gu Y; Lu W; Liu X; Fu H Pathol Res Pract; 2018 Sep; 214(9):1362-1369. PubMed ID: 30060981 [TBL] [Abstract][Full Text] [Related]
13. Upregulated fascin1 in non-small cell lung cancer promotes the migration and invasiveness, but not proliferation. Zhao J; Zhou Y; Zhang Z; Tian F; Ma N; Liu T; Gu Z; Wang Y Cancer Lett; 2010 Apr; 290(2):238-47. PubMed ID: 19819618 [TBL] [Abstract][Full Text] [Related]
14. TGF-β1-induced Fascin1 promotes cell invasion and metastasis of human 786-0 renal carcinoma cells. Huang W; Cen S; Kang XL; Wang WF; Wang Y; Chen X Acta Histochem; 2016 Mar; 118(2):144-51. PubMed ID: 26749573 [TBL] [Abstract][Full Text] [Related]
15. TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Fu H; Hu Z; Wen J; Wang K; Liu Y Acta Biochim Biophys Sin (Shanghai); 2009 Aug; 41(8):648-56. PubMed ID: 19657566 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer. Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558 [TBL] [Abstract][Full Text] [Related]
17. Conversion of raltegravir carrying a 1,3,4-oxadiazole ring to a hydrolysis product upon pH changes decreases its antiviral activity. Nakamura T; Okumura M; Takamune N; Hirotsu T; Sugiura M; Yasunaga J; Nakata H PNAS Nexus; 2024 Jan; 3(1):pgad446. PubMed ID: 38170115 [TBL] [Abstract][Full Text] [Related]
18. Fascin1 expression predicts poor prognosis in patients with nasopharyngeal carcinoma and correlates with tumor invasion. Wu D; Chen L; Liao W; Ding Y; Zhang Q; Li Z; Liu L Ann Oncol; 2010 Mar; 21(3):589-596. PubMed ID: 19759191 [TBL] [Abstract][Full Text] [Related]
19. Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database. Rusconi S; Vitiello P; Adorni F; Bruzzone B; De Luca A; Micheli V; Meraviglia P; Maserati R; Di Pietro M; Colao G; Penco G; Di Biagio A; Punzi G; Monno L; Zazzi M; Clin Microbiol Infect; 2013 Oct; 19(10):936-42. PubMed ID: 23289841 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer. Saito R; Shirakawa R; Nishiyama H; Kobayashi T; Kawato M; Kanno T; Nishizawa K; Matsui Y; Ohbayashi T; Horiguchi M; Nakamura T; Ikeda T; Yamane K; Nakayama E; Nakamura E; Toda Y; Kimura T; Kita T; Ogawa O; Horiuchi H Oncogene; 2013 Feb; 32(7):894-902. PubMed ID: 22450745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]